MX2022010513A - Metodos para tratar esclerosis multiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton. - Google Patents

Metodos para tratar esclerosis multiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton.

Info

Publication number
MX2022010513A
MX2022010513A MX2022010513A MX2022010513A MX2022010513A MX 2022010513 A MX2022010513 A MX 2022010513A MX 2022010513 A MX2022010513 A MX 2022010513A MX 2022010513 A MX2022010513 A MX 2022010513A MX 2022010513 A MX2022010513 A MX 2022010513A
Authority
MX
Mexico
Prior art keywords
methods
multiple sclerosis
bruton
inhibitor
progressive multiple
Prior art date
Application number
MX2022010513A
Other languages
English (en)
Inventor
Hideki Garren
Edmond Huatung Teng
Aurelien Viaccoz
BUEDINGEN Hans- Christian VON
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2022010513A publication Critical patent/MX2022010513A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

En la presente se proporcionan métodos para tratar esclerosis múltiple progresiva primaria (PPMS) en un sujeto que lo necesita, al administrar al sujeto alrededor de 200 mg de fenebrutinib dos veces por día, o una cantidad equivalente de una sal de este farmacéuticamente aceptable.
MX2022010513A 2020-02-28 2021-02-25 Metodos para tratar esclerosis multiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton. MX2022010513A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062982872P 2020-02-28 2020-02-28
US202063051756P 2020-07-14 2020-07-14
PCT/US2021/019502 WO2021173740A1 (en) 2020-02-28 2021-02-25 Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton's tyrosine kinase

Publications (1)

Publication Number Publication Date
MX2022010513A true MX2022010513A (es) 2022-09-21

Family

ID=74885089

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010513A MX2022010513A (es) 2020-02-28 2021-02-25 Metodos para tratar esclerosis multiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton.

Country Status (13)

Country Link
US (1) US20230091561A1 (es)
EP (1) EP4110339A1 (es)
JP (1) JP2023515528A (es)
KR (1) KR20220148826A (es)
CN (1) CN115175682A (es)
AU (1) AU2021227674A1 (es)
BR (1) BR112022017102A2 (es)
CA (1) CA3170685A1 (es)
CL (1) CL2022002317A1 (es)
IL (1) IL295476A (es)
MX (1) MX2022010513A (es)
TW (1) TWI899163B (es)
WO (1) WO2021173740A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021249129A1 (en) 2020-04-03 2022-10-20 F. Hoffmann-La Roche Ag Methods of treating relapsing Multiple Sclerosis using an inhibitor of Bruton's tyrosine kinase
CN114028393B (zh) * 2021-11-07 2023-07-18 天津医科大学 阿帕替尼在制备治疗多发性硬化症药物的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
EP4732904A2 (en) * 2015-10-06 2026-04-29 F. Hoffmann-La Roche AG Method for treating multiple sclerosis
EP4049660B1 (en) 2016-02-29 2025-02-19 F. Hoffmann-La Roche AG Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
CN110382052A (zh) * 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
MX2021000094A (es) * 2018-07-20 2021-03-25 Merck Patent Gmbh Compuesto de amino-pirimidina sustituido para usarse en un metodo para tratamiento y prevencion de esclerosis multiple.
AU2021249129A1 (en) * 2020-04-03 2022-10-20 F. Hoffmann-La Roche Ag Methods of treating relapsing Multiple Sclerosis using an inhibitor of Bruton's tyrosine kinase

Also Published As

Publication number Publication date
CN115175682A (zh) 2022-10-11
KR20220148826A (ko) 2022-11-07
US20230091561A1 (en) 2023-03-23
WO2021173740A1 (en) 2021-09-02
JP2023515528A (ja) 2023-04-13
CL2022002317A1 (es) 2023-03-03
EP4110339A1 (en) 2023-01-04
AU2021227674A1 (en) 2022-07-21
CA3170685A1 (en) 2021-09-02
TW202146022A (zh) 2021-12-16
TWI899163B (zh) 2025-10-01
IL295476A (en) 2022-10-01
BR112022017102A2 (pt) 2022-11-16

Similar Documents

Publication Publication Date Title
MX2022012310A (es) Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton.
MX2022013647A (es) Imidazopiridazinas como moduladores de il-17.
MX2025005489A (es) Uso de lumateperona para el tratamiento del trastorno bipolar ii
MX2025015186A (es) Inhibidores de pi3k y uso de estos
PH12019502334A1 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
MX2023002323A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2024014626A (es) Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton
MX2021012705A (es) Compuestos con actividad antitumoral contra las celulas cancerosas que portan mutaciones en el receptor del factor de crecimiento epidermico (egfr) resistentes al inhibidor de la tirosina quinasa.
MX2024003772A (es) Compuestos de imidazopiridazina inhibidores de il-17.
EP4520398A3 (en) Treatment of prostate cancer
MX2024003770A (es) Compuestos de imidazopiridazina inhibidores de il-17.
MY199779A (en) Pyrrolopyrimidine compound and use thereof
ZA202000028B (en) Use of vibegron to treat overactive bladder
MX2024011249A (es) Dosificacion no lineal de mirdametinib.
MX2022010513A (es) Metodos para tratar esclerosis multiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton.
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
MX2023013225A (es) Inhibidores de la cinasa 4 similar a polo.
MX2024015988A (es) Inhibidores terapeuticos de la tirosina cinasa para la esclerosis multiple y la miastenia grave
WO2021242844A8 (en) Grk2 inhibitors and uses thereof
PH12021550741A1 (en) Vibegron for the treatment of overactive bladder symptoms
PH12021551276A1 (en) Combination therapy for the treatment of cancer
PH12021551975A1 (en) Use of vibegron to treat overactive bladder
ZA202407245B (en) Novel use of pitolisant for treating severe fatigue
MX2025000582A (es) Inhibidores de tirosina cinasa 2 y usos de estos
WO2024039883A3 (en) Compositions and methods to treat myeloproliferative disorders and myeloproliferative neoplasms